Log in
Enquire now
‌

US Patent 7622116 Method of treating inflammation using soluble IL-17RCX4

Patent 7622116 was granted and assigned to ZymoGenetics on November, 2009 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent
1

Patent attributes

Current Assignee
ZymoGenetics
ZymoGenetics
1
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
1
Patent Number
76221161
Patent Inventor Names
Rolf E. Kuestner1
Zeren Gao1
Mark W. Rixon1
Steven D. Levin1
Date of Patent
November 24, 2009
1
Patent Application Number
116730941
Date Filed
February 9, 2007
1
Patent Citations Received
‌
US Patent 11788066 Antibody conjugates and methods of making and using the same
Patent Primary Examiner
‌
Robert Landsman
1
Patent abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7622116 Method of treating inflammation using soluble IL-17RCX4

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.